NCM
KPRX icon

Nantahala Capital Management’s Kiora Pharmaceuticals KPRX Stock Holding History

Nantahala Capital Management’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-106,156
Closed -$209K – 164
2025
Q4 		$209K Sell
106,156
-50,271
-32% -$115K 0.01% 147
2025
Q3 		$435K Sell
156,427
-54,683
-26% -$150K 0.02% 148
2025
Q2 		$608K Hold
211,110
– – 0.02% 144
2025
Q1 		$635K Hold
211,110
– – 0.03% 131
2024
Q4 		$697K Hold
211,110
– – 0.03% 122
2024
Q3 		$773K Hold
211,110
– – 0.04% 118
2024
Q2 		$887K Sell
211,110
-1
-0% -$5 0.05% 106
2024
Q1 		$1.34M Buy
+211,111
New +$1.18M 0.08% 97

Other funds holding KPRX

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Nantahala Capital Management's KPRX Position: Q1 2026 in Review

Nantahala Capital Management sold out of Kiora Pharmaceuticals (KPRX) in Q1 2026, closing a stake of 106,156 shares — an estimated $209K sold.

Nantahala Capital Management first reported a position in KPRX in Q1 2024 and held it in 8 quarters. The position peaked at $1.34M in Q1 2024. 18 funds tracked by Wall St. Rank hold KPRX as of Q1 2026.

  • Nantahala Capital Management reported no remaining Kiora Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Nantahala Capital Management sold 106,156 Kiora Pharmaceuticals shares in Q1 2026, an estimated $209K.
  • Nantahala Capital Management first reported a position in Kiora Pharmaceuticals in Q1 2024 and held it in 8 quarters.
  • Nantahala Capital Management's Kiora Pharmaceuticals position peaked at $1.34M in Q1 2024.
  • 18 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.